Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.3501
Abstract: Importance Patterns-of-failure studies suggest that in metastatic non–small-cell lung cancer (NSCLC) sites of gross disease at presentation are the first to progress when treated with chemotherapy. This knowledge has led to increased adoption of local… read more here.
Keywords: chemotherapy; disease; maintenance chemotherapy; sabr ... See more keywords
Real-World Outcomes of Patients Treated With Neoadjuvant Imatinib for Locally Advanced, Recurrent and Limited Metastatic Gastrointestinal Stromal Tumour in an Australian Cancer Training Network.
Sign Up to like & getrecommendations! Published in 2025 at "Asia-Pacific journal of clinical oncology"
DOI: 10.1111/ajco.70034
Abstract: BACKGROUND Imatinib for palliative and adjuvant treatment of gastrointestinal stromal tumours (GISTs) with common KIT mutations has been revolutionary. For patients with locally advanced, limited metastatic or recurrent disease, neoadjuvant imatinib may downstage the tumour,… read more here.
Keywords: imatinib; neoadjuvant imatinib; locally advanced; limited metastatic ... See more keywords
Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial
Sign Up to like & getrecommendations! Published in 2025 at "BMC Cancer"
DOI: 10.1186/s12885-025-14331-5
Abstract: Limited metastatic gastric cancer (lmGC) represents an intermediate disease stage, positioned between localized and widely disseminated gastric cancer, and has garnered increasing attention due to its distinct prognostic outcomes. Currently, there is no consensus on… read more here.
Keywords: treatment; systemic treatment; metastatic gastric; trial ... See more keywords